Targets › TMSB4X
1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout Feb 2027.
Plays an important role in the organization of the cytoskeleton. Binds to and sequesters actin monomers (G actin) and therefore inhibits actin polymerization..; FUNCTION: [Hemoregulatory peptide AcSDKP]: Potent inhibitor of bone marrow derived stem cell differentiation. (UniProt, P62328)
Open in Phaseline: the race on TMSB4X, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hudson Biotech | TB-500 Thymosin beta 4 17-23 fragment | TMSB4X | Phase 1 | Atherosclerotic Cardiovascular Diseases | Feb 2027 |
Atherosclerotic Cardiovascular Diseases (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.